IBI3033
/ Innovent Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 31, 2025
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
First-in-human • New P1 trial
1 to 1
Of
1
Go to page
1